Cardiomyopathy/Myocarditis
RSSArticles
-
Prevention of Postoperative Atrial Fibrillation
-
Predictive Value of Coronary Pressure Measurements After Stenting
-
Reliability of Doppler Echo for Valvular Regurgitation
-
Sudden Death After Radiofrequency Ablation of the Atrioventricular Node
-
Hot Plaques in Acute Coronary Syndromes?
-
Can Beta-Blockers Prevent Anthracycline-Induced Cardiomyopathy?
Anthracyclines may produce cardiotoxicity by apoptosis and free radical formation. Carvedilol, in addition to being a nonselective beta-blocker and alpha 1 blocker, is antioxidant and antiapoptotic. -
Biomarkers, Better Than Conventional Risk Factors?
In recent years there has been considerable interest in the utilization of biomarkers to assist in the prediction of risk for cardiovascular events, including mortality. -
Can Chemotherapy Cardiotoxicity Be Prevented?
The cardiotoxicity of anthracyclines and other agents may negatively affect clinical outcomes in cancer survivors. Data in other clinical situations and animal data on anthracycline-induced cardiomyopathy suggests that angiotensin-converting enzyme inhibitors (ACEI) may ameliorate this cardiotoxicity. -
Do All Brugada Patients Need an ICD?
Sacher and colleagues collected data on all patients diagnosed with Brugada syndrome who received an implantable cardioverter defibrillator (ICD) in 14 centers between 1993 and 2005. -
The Best Stent for Saphenous Vein Grafts Is?
After 8-10 years, atherosclerosis of saphenous vein grafts and symptoms of ischemia are common. Since repeat bypass surgery is associated with a higher mortality than first surgeries, percutaneous interventions (PCI) are preferred for vein graft disease.